
Deborah H Yates

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/679135/publications.pdf Version: 2024-02-01



Πεβορλή Η Υλτές

#	Article	IF	CITATIONS
1	Artificial stone-associated silicosis: a rapidly emerging occupational lung disease. Occupational and Environmental Medicine, 2018, 75, 3-5.	2.8	137
2	Asbestos and the lung in the 21st century: an update. Clinical Respiratory Journal, 2014, 8, 1-10.	1.6	130
3	Soluble Mesothelin-related Protein in an Asbestos-exposed Population. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 832-837.	5.6	105
4	A breath test for malignant mesothelioma using an electronic nose. European Respiratory Journal, 2012, 40, 448-454.	6.7	105
5	Role of exhaled nitric oxide in asthma. Immunology and Cell Biology, 2001, 79, 178-190.	2.3	101
6	Passive Smoke Inhalation Decreases Exhaled Nitric Oxide in Normal Subjects. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1043-1046.	5.6	79
7	Fractional exhaled nitric oxide in asthma: an update. Respirology, 2010, 15, 57-70.	2.3	66
8	Coal workers' pneumoconiosis: an Australian perspective. Medical Journal of Australia, 2016, 204, 414-418.	1.7	58
9	Detection of gastro-oesophageal reflux disease (GORD) in patients with obstructive lung disease using exhaled breath profiling. Journal of Breath Research, 2012, 6, 016003.	3.0	52
10	Projected mesothelioma incidence in men in New South Wales. Occupational and Environmental Medicine, 2007, 64, 747-752.	2.8	51
11	Nitric Oxide and Exhaled Breath Nitrite/Nitrates in Chronic Obstructive Pulmonary Disease Patients. Respiration, 2007, 74, 617-623.	2.6	51
12	Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. Scandinavian Journal of Work, Environment and Health, 2007, 33, 286-292.	3.4	51
13	Clinical consequences of asbestos-related diffuse pleural thickening: A review. Journal of Occupational Medicine and Toxicology, 2008, 3, 20.	2.2	50
14	Exhaled breath condensate biomarkers in asbestos-related lung disorders. Respiratory Medicine, 2009, 103, 1091-1097.	2.9	36
15	Exhaled breath condensate (EBC) biomarkers in pulmonary fibrosis. Journal of Breath Research, 2012, 6, 016004.	3.0	34
16	Fractional exhaled nitric oxide concentration is increased in asbestosis and pleural plaques. Respirology, 2006, 11, 325-329.	2.3	33
17	Osteopontin Levels in an Asbestos-Exposed Population. Clinical Cancer Research, 2009, 15, 1362-1366.	7.0	27
18	Breath analysis in asbestos-related disorders: a review of the literature and potential future applications. Journal of Breath Research, 2010, 4, 034001.	3.0	27

DEBORAH H YATES

#	Article	IF	CITATIONS
19	Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clinical Chemistry and Laboratory Medicine, 2010, 48, 869-74.	2.3	26
20	Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis. Medical Journal of Australia, 2013, 199, 121-123.	1.7	26
21	Non-invasive assessment of exhaled biomarkers in lung transplantation. Journal of Breath Research, 2011, 5, 024001.	3.0	23
22	Asbestos exposure during home renovation in New South Wales. Medical Journal of Australia, 2013, 199, 410-413.	1.7	23
23	Silica Exposure and Connective Tissue Disease: An Underrecognized Association in Three Australian Artificial Stone Workers. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 378-380.	5.6	23
24	Respiratory surveillance for coal mine dust and artificial stone exposed workers in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*. Respirology, 2020, 25, 1193-1202.	2.3	22
25	Asbestos-related Occupational Lung Diseases in NSW, Australia and Potential Exposure of the General Population. Industrial Health, 2008, 46, 535-540.	1.0	22
26	Prehospital management of exacerbations of asthma: Relation to patient and disease characteristics. Respirology, 2000, 5, 45-50.	2.3	21
27	Complicated silicosis resulting from occupational exposure to engineered stone products. Medical Journal of Australia, 2017, 206, 385-386.	1.7	21
28	mTOR treatment in lymphangioleiomyomatosis: the role of everolimus. Expert Review of Respiratory Medicine, 2016, 10, 249-260.	2.5	20
29	Occupational asthma in New South Wales (NSW): a population-based study. Occupational Medicine, 2006, 56, 258-262.	1.4	16
30	Occupational exposure to asbestos in New South Wales, Australia (1970-1989): development of an asbestos task exposure matrix. Occupational and Environmental Medicine, 2010, 67, 201-206.	2.8	16
31	Respiratory surveillance in mineral dust-exposed workers. Breathe, 2020, 16, 190632.	1.3	12
32	Factors affecting female or male consultant stress in an Australian teaching hospital. Medical Journal of Australia, 2003, 179, 174-175.	1.7	12
33	Burnout and psychiatric morbidity in new medical graduates. Medical Journal of Australia, 2005, 182, 599-599.	1.7	11
34	Influenza vaccination: Changes in exhaled nitric oxide levels and sputum cytology. Respirology, 1999, 4, 355-358.	2.3	10
35	Association of Biomarker Levels with Severity of Asbestos-Related Diseases. Safety and Health at Work, 2012, 3, 17-21.	0.6	10
36	Lung Function Profiles among Individuals with Nonmalignant Asbestos-related Disorders. Safety and Health at Work, 2014, 5, 234-237.	0.6	7

Deborah H Yates

#	Article	IF	CITATIONS
37	Multifocal Micronodular Pneumocyte Hyperplasia in Tuberous Sclerosis Complex: Resolution with Everolimus Treatment. American Journal of Respiratory and Critical Care Medicine, 2020, 201, e76-e76.	5.6	7
38	<scp>Workâ€related</scp> asthma: A position paper from the Thoracic Society of Australia and New Zealand and the National Asthma Council Australia. Respirology, 2020, 25, 1183-1192.	2.3	7
39	Early detection of malignant pleural mesothelioma through measurement of soluble mesothelinâ€related protein and positron emission tomography. Medical Journal of Australia, 2009, 190, 158-159.	1.7	6
40	A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels. Clinical Chemistry and Laboratory Medicine, 2012, 50, 2199-2204.	2.3	4
41	Down Under in the Coal Mines. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 772-773.	5.6	4
42	Dust diseases in modern Australia: a discussion of the new TSANZ position statement on respiratory surveillance. Medical Journal of Australia, 2021, 215, 13.	1.7	4
43	Medical diagnosis at the point-of-care by portable high-field asymmetric waveform ion mobility spectrometry: a systematic review and meta-analysis. Journal of Breath Research, 2021, 15, 046002.	3.0	4
44	Pleuroperitoneal Denver shunt insertion for the treatment of refractory chylothorax in a patient with tuberous sclerosis complex and lymphangioleiomyomatosis. Internal Medicine Journal, 2017, 47, 1463-1464.	0.8	2
45	Investigating cystic lung disease: a respiratory detective approach. Breathe, 2020, 16, 200041.	1.3	2
46	Asbestos: insights from women. Lancet Respiratory Medicine,the, 2017, 5, 782-784.	10.7	1
47	Asbestos exposure during home renovation in New South Wales. Medical Journal of Australia, 2014, 200, 315-315.	1.7	0
48	Dustâ€related diffuse fibrosis in a coal mine worker from New South Wales. Medical Journal of Australia, 2022, , .	1.7	0
49	Mind the gaps: Occupational and environmental exposures in interstitial lung diseases. Respirology, 0, , .	2.3	0